Inhibrx Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Inhibrx Biosciences

13/08/2026 21:22

Inhibrx Biosciences Inc INBX.OQ reported a quarterly adjusted loss of $2.34​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.85.  The mean expectation of two analysts for the quarter was for a loss of $2.39 per share. Wall Street expected results to range from $-2.50 to $-2.28 per share.
Reported revenue was zero​; analysts expected zero. 
Inhibrx Biosciences Inc's reported EPS for the quarter was a loss of $2.34​.
The company reported a quarterly loss of $36.65 million.
Inhibrx Biosciences Inc shares had risen by 3.8% this quarter and gained 24.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 24.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $277.50, about 64.6% above its last closing price of $98.36
This summary was machine generated from LSEG data August 13 at 08:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-2.39
-2.34
Beat
Mar. 31 2026 
-1.79
-2.15
Missed
Dec. 31 2025 
-2.08
-2.11
Missed
Sep. 30 2025 
-1.72
-2.28
Missed